Cancer News and Research

Latest Cancer News and Research

Xenex Healthcare Services announces commercial launch of pulsed xenon room disinfection system

Xenex Healthcare Services LLC, which specializes in developing disinfection technology for healthcare facilities, today announced the commercial launch of its pulsed xenon room disinfection system and the conclusion of the Xenex system's successful trial at a leading U.S. cancer center. The Xenex system, which is now available, is the fastest, safest, and most effective method for the advanced cleaning of hospital rooms in the world today, quickly destroying all major classes of microorganisms (including viruses, bacteria and bacterial spores) without contact or chemicals.

8 Jun 2010

GTx reports positive results from toremifene Phase III clinical trial

GTx, Inc. announced today that in the Phase III clinical trial evaluating toremifene 80 mg for the reduction of fractures and treatment of other estrogen deficiency side effects in men with prostate cancer on androgen deprivation therapy (ADT), toremifene treatment demonstrated an improved benefit/risk ratio in men less than 80 years of age. The data were presented yesterday at the 2010 Annual Meeting of the American Society of Clinical Oncology in Chicago.

8 Jun 2010

CMAJ to publish comprehensive new guidelines on immigrant health

CMAJ will publish a ground-breaking series of comprehensive new guidelines on immigrant health (pre-embargo link only) beginning June 7, 2010 . The Canadian Immigrant Health Guidelines, a multi-part series, will assist clinicians, policy makers and immigrants in understanding the diverse needs of immigrants to Canada. Few resources like this exist in the international medical literature.

8 Jun 2010

ZixCorp announces new, 3-year email encryption contract with Orlando Health

Zix Corporation, the leader in email encryption services, has announced a new, three-year contract with Orlando Health, a $1.5 billion not-for-profit health care organization and a community-based network of hospitals and care centers in the Orlando region.

8 Jun 2010

SciMed Technologies receives certification for VitaKit A from AOAC International

SciMed Technologies Inc. today announces they received certification from the AOAC International - a worldwide scientific association dedicated to analytical excellence - for VitaKit A the world's first 2 hour rapid test for accurate analysis of vitamin A in liquid milk.

8 Jun 2010

Idera reports preliminary results from IMO-3100 Phase 1 clinical trial for autoimmune, inflammatory diseases

Idera Pharmaceuticals, Inc. today announced preliminary results from a Phase 1 clinical trial of IMO-3100, its lead Toll-like Receptor (TLR) 7 and TLR9 antagonist drug candidate for potential applications in autoimmune and inflammatory diseases. In this trial, healthy subjects in five dosage cohorts received single doses of IMO-3100 from 0.04 to 0.64 mg/kg. IMO-3100 was well tolerated at all dose levels.

8 Jun 2010

FDA grants Cepheid marketing clearance for Xpert SA Nasal Complete molecular test

Cepheid today announced it has received clearance from the U.S. Food & Drug Administration (FDA) to market Xpert® SA Nasal Complete, the first and only molecular test designed for the simultaneous detection and differentiation of both Staphylococcus aureus (SA) and Methicillin-resistant Staphylococcus aureus (MRSA) colonization in less than one hour. The test runs on Cepheid's GeneXpert® System, the world's leading molecular platform for accuracy, speed, and ease-of-use.

8 Jun 2010

New technique to prevent tumours developing in connection with stem cell transplantations

Researchers at Lund University have come up with a new technique to prevent tumours developing in connection with stem cell transplantations. The results have been published today in the respected scientific journal PNAS.

8 Jun 2010

Research project to transform primary care practices into patient-centered medical homes concludes

An unprecedented research project into how to transform primary care practices into patient-centered medical homes has concluded with the release of a new eight-paper supplement to the May/June issue of Annals of Family Medicine.

8 Jun 2010

Boosting levels of ABCG1 protein in diabetics will improve insulin production

If you think of diabetes onset like an elaborate molecular drama, then a research team led by a La Jolla Institute scientist has unmasked a previously unknown cellular player, which is critical to proper insulin secretion. "Defective insulin secretion is a hallmark of both type 1 and type 2 diabetes," said Catherine Hedrick, Ph.D., a scientist at the La Jolla Institute for Allergy & Immunology, who led the team, which included researchers from the University of Virginia.

8 Jun 2010

MicroStockProfit.com: ARIA reports net loss of $23.4M for three months ended March 31, 2010

MicroStockProfit.com announces an investment report featuring ARIAD Pharmaceuticals Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

8 Jun 2010

Combined cardiac bypass and liver tumor surgery performed on 63-year-old Nigerian

Adding another feat to the history of cardiothoracic surgery at Fortis Hospitals Bangalore, the team of experts led by noted Dr. Vivek Jawali, Chief Cardiothoracic Surgeon and Dr. Ramcharan Thiagarajan, Consultant Surgical GI & Hepato-Pancreatic Biliary Surgoen has performed a combined cardiac bypass and liver tumor surgery on a 63 year old Nigerian.

8 Jun 2010

Elotuzumab shows promise in treating multiple myeloma: Study

A drug designed to target cancerous plasma cells appears promising in treating multiple myeloma, a type of blood cancer. A multi-center study looked at the drug elotuzumab, an antibody which is designed to target CS1, a protein on the surface of malignant plasma cells. The antibody has the potential to attach to malignant plasma cells and eliminates them by an immune mechanism.

8 Jun 2010

Clarient granted U.K. patent for TLE3 biomarker

Clarient, Inc., a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced that the United Kingdom Patent Office has granted a U.K. patent on the Company's TLE3 biomarker, a marker which may be used to predict which cancer patients will respond favorably to taxane therapy.

8 Jun 2010

Give a Scan: First open access website for CT scans and clinical data

Lung Cancer Alliance, the only national non-profit dedicated to providing support and advocacy for those living with or at risk for lung cancer, announced today the launching of the first open access website for CT scans and clinical data donated by patients, called Give a Scan, that will increase and accelerate research for lung cancer screening, diagnosis, treatment and drug development.

8 Jun 2010

Experimental drug that targets genetic makeup of tumor shows early signs of efficacy against medulloblastomas

Researchers from St. Jude Children's Research Hospital and the Pediatric Brain Tumor Consortium (PBTC) presented at the American Society of Clinical Oncology the findings of a pediatric brain tumor study using an experimental drug that targets the underlying genetic makeup of the tumor. The research focused on a new way to attack the tumors by blocking the Hedgehog pathway that is linked to approximately 20 percent of medulloblastomas.

8 Jun 2010

Scientists combine two agents to treat patients with multiple myeloma

Scientists from the Barbara Ann Karmanos Cancer Institute in Detroit presented data showing that by combining two treatment agents in the care of multiple myeloma patients, doctors can use higher dosages of chemotherapy before autologous stem cell transplant while alleviating painful and debilitating side effects like severe oral mucositis (mouth ulcers).

8 Jun 2010

$Phase 2 Study: NKTR-102 holds great therapeutic potential for women with platinum-resistant/refractory ovarian cancer$

Phase 2 Study: NKTR-102 holds great therapeutic potential for women with platinum-resistant/refractory ovarian cancer

Nektar Therapeutics today announced positive results from a Phase 2 clinical study evaluating single-agent NKTR-102 in women with platinum-resistant/refractory ovarian cancer. A total of 68 patients were enrolled with platinum-resistant disease, half of whom were platinum refractory. All 68 patients were evaluable for the primary endpoint of objective response rate using Gynecologic Cancer InterGroup criteria, which is a combination of response by tumor imaging (RECIST) and/or ovarian cancer biomarker (CA-125) criteria.

8 Jun 2010

Findings from Abraxis BioScience's phase 3 ABRAXANE trial in patients with NSCLC presented at ASCO

Abraxis BioScience, Inc. announced today that findings from their phase 3 randomized trial of nanoparticle albumin bound driven chemotherapy, nab-paclitaxel (ABRAXANE for Injectable Suspension; paclitaxel albumin protein-bound particles for injectable suspension) plus carboplatin, showed a statistically significant 31 percent improvement in overall response rate when compared with Taxol (paclitaxel) injection plus carboplatin in the first-line treatment of patients with non-small cell lung cancer.

8 Jun 2010

Chemotherapy drug sunitinib promising for HIV-positive cancer patients

Preliminary findings from a unique study with sunitinib suggest that it might be possible to tweak the dosage of chemotherapy drugs used to treat HIV-positive cancer patients to achieve therapeutic benefit. Given the type of drug cocktail patients use to treat their HIV, much more or considerably less chemotherapy may be warranted, say the researchers, part of the NCI-supported AIDS Malignancy Consortium (AMC). The trial design is being presented at the 2010 annual meeting of the American Society of Clinical Oncology (ASCO).

8 Jun 2010

Cancer News and Research

Latest Cancer News and Research

Xenex Healthcare Services announces commercial launch of pulsed xenon room disinfection system

GTx reports positive results from toremifene Phase III clinical trial

CMAJ to publish comprehensive new guidelines on immigrant health

ZixCorp announces new, 3-year email encryption contract with Orlando Health

SciMed Technologies receives certification for VitaKit A from AOAC International

Idera reports preliminary results from IMO-3100 Phase 1 clinical trial for autoimmune, inflammatory diseases

FDA grants Cepheid marketing clearance for Xpert SA Nasal Complete molecular test

New technique to prevent tumours developing in connection with stem cell transplantations

Research project to transform primary care practices into patient-centered medical homes concludes

Boosting levels of ABCG1 protein in diabetics will improve insulin production

MicroStockProfit.com: ARIA reports net loss of $23.4M for three months ended March 31, 2010

Combined cardiac bypass and liver tumor surgery performed on 63-year-old Nigerian

Elotuzumab shows promise in treating multiple myeloma: Study

Clarient granted U.K. patent for TLE3 biomarker

Give a Scan: First open access website for CT scans and clinical data

Experimental drug that targets genetic makeup of tumor shows early signs of efficacy against medulloblastomas

Scientists combine two agents to treat patients with multiple myeloma

Phase 2 Study: NKTR-102 holds great therapeutic potential for women with platinum-resistant/refractory ovarian cancer

Findings from Abraxis BioScience's phase 3 ABRAXANE trial in patients with NSCLC presented at ASCO

Chemotherapy drug sunitinib promising for HIV-positive cancer patients

Understanding the DNA Damage Response in Innate Immunity eBook

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Cancer News and Research

Latest Cancer News and Research

Understanding the DNA Damage Response in Innate Immunity eBook

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Newsletters you may be interested in